Chimeric nucleic acids encoding polypeptides comprising CD70 and Fas ligand domains
This invention relates to genes which encode accessory molecule ligands and their use for immunomodulation, vaccination and treatments of various human diseases, including malignancies and autoimmune diseases. This invention also describes the use of accessory molecule ligands which are made up of various domains and subdomain portions of molecules derived from the tumor necrosis factor family. The chimeric molecules of this invention contain unique properties which lead to the stabilization of their activities and thus greater usefulness in the treatment of diseases. Vectors for expressing genes which encode the accessory molecule ligands of this invention are also disclosed.
1. A chimeric nucleic acid molecule comprising a first polynucleotide encoding CD70 Domain III and a second polynucleotide encoding Fas ligand (FasL) Domain IV.
2. The chimeric nucleic acid molecule according to claim 1 , wherein the CD70 Domain III lacks a matrix metalloproteinase cleavage site, and the FasL Domain IV contains a binding site for CD95.
3. The chimeric nucleic acid molecule according to claim 1 , wherein the first polynucleotide further encodes Domain II from CD70 or FasL.
4. The chimeric nucleic acid molecule according to claim 3 , wherein the first polynucleotide further encodes Domain I from CD70 or FasL.
5. An expression vector comprising the chimeric nucleic acid molecule according to claim 1 .
6. A genetic construct comprising the chimeric nucleic acid molecule according to claim 1 .
7. A host cell comprising the expression vector according to claim 5 .
8. A host cell comprising the genetic construct according to claim 6 .
9. A chimeric nucleic acid molecule comprising a first polynucleotide which encodes human Fas ligand (FasL) Domain III and a second polynucleotide which encodes non-human FasL Domain IV.
10. The chimeric nucleic acid molecule according to claim 9 , wherein the human FasL Domain III lacks a matrix metalloproteinase cleavage site, and the non-human FasL Domain IV contains a binding site for CD95.
11. The chimeric nucleic acid molecule according to claim 7 , wherein the first polynucleotide further encodes Domain II from human or non-human FasL.
12. The chimeric nucleic acid molecule according to claim 7 , wherein the first polynucleotide further encodes Domain I from human or non-human FasL.
13. A genetic construct comprising the chimeric nucleic acid molecule according to claim 9 .
14. An expression vector comprising the chimeric nucleic acid molecule according to claim 9 .
15. A host cell comprising the genetic construct according to claim 13 .
16. A host cell comprising the expression vector according to claim 14 .
17. A chimeric nucleic acid molecule comprising a first polynucleotide which encodes non-human Fas ligand (FasL) Domain III and a second polynucleotide which encodes human FasL Domain IV.
18. The chimeric nucleic acid molecule according to claim 17 , wherein the non-human FasL Domain III lacks a matrix metalloproteinase cleavage site, and the human FasL Domain IV contains a binding site for CD95.
19. The chimeric nucleic acid molecule according to claim 17 , wherein the first polynucleotide further encodes Domain II from non-human or human FasL.
20. The chimeric nucleic acid molecule according to claim 19 , wherein the first polynucleotide further encodes Domain I from non-human or human FasL.
21. A genetic construct comprising the chimeric nucleic acid molecule according to claim 17 .
22. An expression vector comprising the chimeric nucleic acid molecule according to claim 17 .
23. A host cell comprising the genetic construct according to claim 21 .
24. A host cell comprising the expression vector according to claim 22 .